The Challenge of CMC Regulatory Compliance for Biopharmaceuticals
An effective CMC regulatory compliance strategy for biologics and biopharmaceuticals can seem like a mystery. Through means of this 2nd edition, this no longer needs to occur. A great deal of thanks goes to two regulatory authorities – the United States Food and Drug Administration (FDA) and the E...
保存先:
| 第一著者: | |
|---|---|
| 団体著者: | |
| フォーマット: | 電子媒体 eBook |
| 言語: | English |
| 出版事項: |
New York, NY :
Springer New York : Imprint: Springer,
2013.
|
| 版: | 2nd ed. 2013. |
| 主題: | |
| オンライン･アクセス: | https://doi.org/10.1007/978-1-4614-6916-2 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
目次:
- Complexity of Biologica CMC Regulation
- Biologics are Not Chemical Drugs
- An Effective CMC Strategy is Possible
- Challenge of Adventitious Agent Control
- Source Materials for Biologics
- Manufacture of the Biologic API
- The Biologic Final Product Process
- Complex Process-Related Impurities
- Molecular Structural Analysis
- Functional Activity (Potency)
- Setting Specifications and Expiry Dates
- Demonstrating Product Comparability
- CMC-Focused Regulatory Meetings
- References.